China
Africa
Explore chapters and articles related to this topic
Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Published in Wojciech Gorczyca, Atlas of Differential Diagnosis in Neoplastic Hematopathology, 2014
Gene expression profiling of WM revealed a homogeneous transcription profile, clustered with chronic lymphoblastic leukemia (CLL) and normal B cells on unsupervised clustering, and clearly had a phenotype more similar to CLL cells than MM [47]. Both WM and B-CLL are low-grade lymphoproliferations derived from memory B-cell populations, which usually lack chromosomal translocations involving the IGH locus. The IGH translocations occur most likely during immunoglobulin VDJ recombination in maturing B cells or during immunoglobulin hypermutation and isotype switching in mature B cells within the germinal center [48]. Despite these similarities, different phenotype (CD5 and CD43 expression in B-CLL) and IGVH mutational status (almost all WM cases are IGVH mutated, compared to ~60% of CLLs) suggest that they may be derived from different memory B-cell populations. Potential genes that may be involved in WM pathogenesis include BLIMP-1 (located on 6q21) and HAS1 genes. MYD88 L265P is a commonly recurring mutation in patients with LPL/WM.
Mechanisms of Fibril Formation and Cellular Response
Published in Martha Skinner, John L. Berk, Lawreen H. Connors, David C. Seldin, XIth International Symposium on Amyloidosis, 2007
Martha Skinner, John L. Berk, Lawreen H. Connors, David C. Seldin
Mice immunized with the Blimp-1-derived mBLIMP470-479 similarly produced potent CTL capable of killing JY cells pulsed with mBLIMP470-479 peptide but not with an irrelevant peptide. Since this peptide sequence is derived from the murine Blimp-1 self-protein, these results demonstrate that tolerance to self proteins such as Blimp-1 can be broken in vivo and support the hypothesis that other targets, such as Ig X6 in humans can similarly be targeted successfully.
A prospective, multi-center, randomised controlled trial for evaluation of the effectiveness of the Blimp scoring balloon in lesions not crossable with a conventional balloon or microcatheter: the BLIMP study
Published in Acta Cardiologica, 2023
J. Dens, W. Holvoet, K. McCutcheon, C. Ungureanu, P. Coussement, S. Haine, Q. De Hemptinne, J. Sonck, W. Eertmans, J. Bennett
Based on the study setup, at the inclusion rate of 128 patients, a minimum of 60 patients will have been treated with the Blimp. Under the assumption that current LP balloon catheters will have a 60% success of crossing after initial failure of a microcatheter crossing and expecting a 80% success rate for Blimp, with a power of 80%, 120 patients were required to demonstrate statistical significance between the groups.